Deadly Fungus Boosts Chinese Pharma 😷

by | 11 Apr, 2019

Deadly Fungus Boosts Chinese Pharma

That’s right folks, a deadly ‘super fungus’ is on the loose, and even though no company has an official cure, investors are diving headlong into pharma stocks as a preemptive strike. Sounds nuts right?

The Candida Auris fungus, which can cause bloodstream, ear and wound infections in patients with a weakened immune system, is said to be spreading and allegedly resistant to treatment and antibiotics. The disease is mostly found in hospitals and healthcare facilities where it spreads via surfaces and human contact. Yikes.

It was first discovered in Japan in 2009, but has resurfaced with a vengeance across the globe, prompting US health authorities to call it “a serious global health threat”. The announcement sparked a wave of investment into the Chinese pharma sector which has bumped up roughly 10-15% in the last three days with some individual companies appreciating as much as 33%.

China’s pharma sector was one of the worst performing components of China’s economy last year after legislation forced producers to lower drug prices significantly across the board. Now, however, they are making a comeback after surprising investors with strong earnings and the recent paranoia surrounding the Candida Auris outbreak. 

Crazy stuff!

All emails include an unsubscribe link. You can opt-out at any time. ​See our privacy policy.

ALL RIGHTS RESERVED © INVSTR LTD. 2018

Risk Disclosure:
Invstr is a technology platform, not a registered broker-dealer or investment adviser. Invstr does not offer its own recommendations of any security or provide its own research to any user regarding any security transaction or order.
Please note, investing involves risk and investments may lose value. Past performance does not guarantee future results.
Brokerage services are provided by the following:
US-traded securities, including fractional trading, are provided to Invstr users by DriveWealth LLC, a regulated member of FINRA/SIPC. DriveWealth may not establish investment accounts to residents of certain jurisdictions. For more information, including disclaimers, risk and transaction fees click here.
India account traded securities are provided by SIC Stocks & Services PVT Ltd. SIC does not make any personal recommendations to buy, sell or otherwise deal in investments. Investors make their own investment decisions. The services and securities provided by SIC may not be suitable for all customers and, if you have any doubts, you should seek advice from an independent financial adviser. For more information and disclaimers, click here.

Download on the App Store           Download on Google Play

ALL RIGHTS RESERVED © INVSTR LTD. 2018

Risk Disclosure:
Invstr is a technology platform, not a registered broker-dealer or investment adviser. Invstr does not offer its own recommendations of any security or provide its own research to any user regarding any security transaction or order.
Please note, investing involves risk and investments may lose value. Past performance does not guarantee future results.
Brokerage services are provided by the following:
US-traded securities, including fractional trading, are provided to Invstr users by DriveWealth LLC, a regulated member of FINRA/SIPC. DriveWealth may not establish investment accounts to residents of certain jurisdictions. For more information, including disclaimers, risk and transaction fees click here.
India account traded securities are provided by SIC Stocks & Services PVT Ltd. SIC does not make any personal recommendations to buy, sell or otherwise deal in investments. Investors make their own investment decisions. The services and securities provided by SIC may not be suitable for all customers and, if you have any doubts, you should seek advice from an independent financial adviser. For more information and disclaimers, click here.

 

Share This